Steve

I, Steve Burns, nominated by Maria Belvisi, residing in UK, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Global Project Leader at Astrazeneca. My responsibilities include the development of new medicines for treatment of Respiratopry and Immunological illness.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I have shares in an entity with an interest in the subject matter of the meeting or work. I hold shares and share options with AstraZeneca
   • Employment, consultancy, directorship or other positions: I am employed by AstraZeneca
   • Government advice and other policy development: None
   • Paid research activities, fellowships or grants: None
   • Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is AstraZeneca
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Steve Burns
Date: 21st April 2021